Immatics (IMTX) Stock Dropped, So What Is Behind The Fresh Attention?

Immatics (IMTX) is back in focus after releasing updated Phase 1b and Phase 1 data for its PRAME-directed therapies IMA402 and IMA203CD8 at the 2026 ESMO conference in Madrid.

The new IMA402 and IMA203CD8 data land after a choppy period for Immatics, with the share price down about 30% year to date and the 1-year total shareholder return declining roughly 28%. In the shorter term, momentum has started to rebuild with an 8.6% 7-day share price gain, despite a weaker 1-day move.

Spot opportunities around Immatics by scanning a hand-picked set of 34 healthcare AI stocks that are also working on cutting-edge cancer and healthcare treatments.

Immatics has fallen sharply this year while analyst targets cluster far above the current US$7.31 share price. The gap is wide. The real puzzle is where fair value sits between those two anchors.

Preferred Price-to-Sales Multiple of 21.4x: Is it justified?

Immatics trades on a P/S ratio of 21.4x at a last close of $7.31, and that valuation benchmark sends a mixed message when set against both peers and its own fundamentals.

The P/S multiple compares the company’s market value to its trailing revenue, so it is often used for early-stage biotechs that do not yet report profits. For Immatics, investors are effectively paying 21.4 times its $41.7m of revenue. This points to a significant focus on the potential of its T cell therapies and collaboration pipeline rather than current income.

On peer comparisons, the picture is split. Immatics looks cheaper than the selected peer average P/S of 25.1x, which suggests the stock is priced more conservatively than some direct biotech comparables. Against the broader US Biotechs industry though, where the average P/S sits at 11.1x, the valuation is almost twice as rich. The contrast is even sharper versus the estimated fair P/S ratio of 0x, which implies the current multiple is far above the level that regression-based fair value work suggests the market could move toward.

Explore the SWS fair ratio for Immatics.

Result: Price-to-Sales of 21.4x (OVERVALUED)

Still, the story around Immatics can change quickly if the early-stage trials stumble or if partners like Moderna, Genmab, or Celgene reassess their commitments.

Find out about the key risks to this Immatics narrative.

Next Steps

Mixed about Immatics after all this data and valuation context. Act while the details are fresh and weigh both sides of the story by reviewing the 1 key reward and 1 important warning sign

Looking for more investment ideas beyond Immatics?

If Immatics has sharpened your focus on healthcare risks and rewards, do not stop here. Broader idea hunting gives you more control over your portfolio.

• Target potential bargains by scanning a 29 high quality undervalued stocks that filters for companies combining quality fundamentals with prices that may sit below their estimated worth.
• Strengthen your income stream by reviewing a 5 dividend fortresses built around businesses offering higher yields with an emphasis on durability.
• Sleep easier at night by examining a 30 resilient stocks with low risk scores that highlights resilient companies with lower risk scores and steadier profiles.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com